TaiTsun (4169) Corrects Misstatements in Q1 2026 Consolidated Financial Report
NQ Score
3/100
N1 Content Completeness
2
AI Summary (NQ-processed)
TaiTsun Biopharmaceutical Co., Ltd. announced a correction to its Q1 2026 (Minguo 115) consolidated financial report. The errors in the cash flow statement involved incorrect signs for 'Interest expense' and 'Interest paid,' and the omission of 'Interest income' and 'Interest received.' The company will correct the relevant consolidated report and iXBRL filing.